RBC Capital Initiates Coverage on Spark Therapeutics Inc to Outperform

RBC Capital Initiates Coverage on Spark Therapeutics Inc(NASDAQ:ONCE). The shares have been rated Outperform. The rating by RBC Capital was issued on Jul 12, 2016.

In a different note, Jefferies said it Initiates Coverage on Spark Therapeutics Inc, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Hold’ by the firm. Cantor Fitzgerald said it Initiates Coverage on Spark Therapeutics Inc, according to a research note issued on Jun 2, 2016. The shares have been rated ‘Buy’ by the firm.

Spark Therapeutics Inc (ONCE) made into the market gainers list on Fridays trading session with the shares advancing 0.02% or 0.01 points. Due to strong positive momentum, the stock ended at $53.08, which is also near the day’s high of $53.78. The stock began the session at $52.9 and the volume stood at 2,87,306 shares. The 52-week high of the shares is $71.7499 and the 52 week low is $21.2. The company has a current market capitalization of $1,454 M and it has 2,73,98,357 shares in outstanding.

Spark Therapeutics Inc(ONCE) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.29M. Analysts had an estimated revenue of $1.48M. Earnings per share were $-0.95. Analysts had estimated an EPS of $-0.84.

Several Insider Transactions has been reported to the SEC. On Jul 7, 2016, Barge Joseph La (officer ) sold 3,000 shares at $52.36 per share price.Also, On Jun 22, 2016, Hospital Of Philade Children’s (10% owner) sold 1,000,000 shares at $42.30 per share price.On Jun 16, 2016, Jeffrey D Marrazzo (Chief Executive Officer) sold 5,000 shares at $47.26 per share price, according to the Form-4 filing with the securities and exchange commission.

Spark Therapeutics Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate SPK-RPE65 which is in Phase III clinical trial stage targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs) caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *